

PharmaZell GmbH

Rosenheimer Str. 43
D-83064 Raubling

T +49 8035 88 337
F +49 8035 88 143
info@pharmazell.com

TO WHOM IT MAY CONCERN

Raubling, February 27, 2013

PharmaZell adds manufacturing site

With pleasure we announce that the PharmaZell group has added an additional European manufacturing site to its production network. The site - formerly owned and operated by Abbott Pharmaceuticals - is located in Liestal, Switzerland, close to Basel, an international life-science region in the heart of Europe.


PharmaZell which since October 2011 is part of the Zellbios group owned by Ergon Capital Partners and the management is taking over the Liestal site from its current owner Drug'On Pharma Switzerland. Since February 1, 2013 the PharmaZell group operates the site as a branch office of PharmaZell GmbH (Germany). Before the official transition our new site has already been inspected by SwissMedic in December 2012 and subsequently licensed to manufacture active pharmaceutical ingredients as well as controlled substances.

Our new site consists of commercial scale, multipurpose manufacturing equipment with a total of 150 m³ of reactor volume along with appropriate drying and milling capacity with packaging clean rooms, a pilot plant and adequate QC labs and warehouses suitable for manufacturing small molecule, large volume APIs. The site is in excellent condition and highly automated.

This move adds a third European manufacturing site to the Zellbios group in addition to PharmaZell headquarters near Munich, Germany and Farmabios near Pavia, Italy. The addition of substantial multi-purpose capacity is in line with the PharmaZell strategy to grow its portfolio of multi-step active pharmaceutical ingredients which will also include controlled substances. PharmaZell will continue to leverage its cGMP API manufacturing plants in Chennai and Vizag in southern India to serve its global client base and provide low-cost advanced intermediates as well as APIs to its European sites.

As of January 18, 2013 PharmaZell has already updated its first CEP for the API Propafenone to include the new Liestal site. Several other APIs will soon be added to the manufacturing portfolio at this site. PharmaZell will provide full regulatory support to its clients including on-site audits to ensure that they can register APIs produced at this manufacturing site in a timely manner.


We are looking forward to growing further with our clients who trust our API quality at an affordable price.



Dr. Oliver Bolzern
CEO



Dr. Wolfgang Burger
Vice President Business Development



Dr. Hans-Peter Wagner
CFO